Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants

Xenobiotica

Volumn 42, Issue 2, 2012, Pages 173-178

  Xiao, C Q ^a   Chen, R ^a   Lin, J ^a   Wang, G ^b   Chen, Y ^b   Tan, Z R ^b   Zhou, H H ^b  

^a THE FIRST PEOPLE S HOSPITAL OF CHENZHOU   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CYP3A; Drug interaction; Genistein; P gp

Indexed keywords

CYTOCHROME P450 3A; GENISTEIN; GLYCOPROTEIN P; MIDAZOLAM; PLACEBO; TALINOLOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHINESE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DOUBLE-BLIND METHOD; GENISTEIN; HERB-DRUG INTERACTIONS; HUMANS; MALE; METABOLIC CLEARANCE RATE; METABOLIC DETOXICATION, DRUG; MIDAZOLAM; P-GLYCOPROTEIN; PROPANOLAMINES; PROTEIN KINASE INHIBITORS;

EID: 84855455673     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.615954     Document Type: Article

References (39)

1. Anderle P, Niederer E, Rubas W, Hilgendorf C, Spahn-Langguth H, Wunderli-Allenspach H, Merkle HP, Langguth P. (1998). P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels. J Pharm Sci 87:757-762. (Pubitemid 28268577)
2. Appelt LC, Reicks MM. (1997). Soy feeding induces phase II enzymes in rat tissues. Nutr Cancer 28:270-275. (Pubitemid 27446655)
3. Appelt LC, Reicks MM. (1999). Soy induces phase II enzymes but does not inhibit dimethylbenz[a]anthracene-induced carcinogenesis in female rats. J Nutr 129:1820-1826. (Pubitemid 29468594)
4. Ariel F. Castro, Guillermo A. Altenberg. (1997) Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-Glycoprotein. Biochem Pharmacol 53:89-93.
5. Axelson M, Sjovall J, Gustafsson BE, Setchell KD. (1984). Soya-a dietary source of the non-steroidal oestrogen equol in man and animals. J Endocrinol 102:49-56. (Pubitemid 14123919)
6. Bernsdorf A, May K, Kuhnert-Keil C, Moritz KU, Kroemer HK, Siegmund W. (2003). Expression of P-glycoprotein and MRP2-deficient rats (GY/TR-) (abstract). Naunyn Schmiedebergs Arch Pharmacol 367:R110.
7. Boersma BJ, Barnes S, Kirk M, Wang CC, Smith M, Kim H, Xu J, Patel R, Darley-Usmar VM. (2001). Soy isoflavonoids and cancer? metabolism at the target site. Mutat Res 480-481:121-127. (Pubitemid 32744819)
8. Borrelli F, Izzo AA. (2009). Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. AAPS J 11:710-727.
9. Borst P, Evers R, Kool M, Wijnholds J. (2000). A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302. (Pubitemid 30662093)
10. Breinholt V, Lauridsen ST, Dragsted LO. (1999). Differential effects of dietary flavonoids on drug metabolizing and antioxidant enzymes in female rat. Xenobiotica 29:1227-1240. (Pubitemid 30019224)
11. Cascorbi I. (2006). Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112:457-473. (Pubitemid 44486412)
12. Chen Y, Xiao CQ, He YJ, Chen BL, Wang G, Zhou G, Zhang W, Tan ZR, Cao S, Wang LP, Zhou HH. (2011). Genistein alters caffeine exposure in healthy female volunteers. Eur J Clin Pharmacol 67:347-353.
13. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC. (1998). Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280:1569-1575. (Pubitemid 28520643)
14. Foster BC, Vandenhoek S, Hana J, Krantis A, Akhtar MH, Bryan M, Budzinski JW, Ramputh A, Arnason JT. (2003). In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 10:334-342. (Pubitemid 36597170)
15. Geick A, Eichelbaum M, Burk O. (2001). Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581-14587.
16. Giessmann T, May K, Modess C, Wegner D, Hecker U, Zschiesche M, Dazert P, Grube M, Schroeder E, Warzok R, Cascorbi I, Kroemer HK, Siegmund W. (2004). Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther 76:192-200. (Pubitemid 39221793)
17. Harborne, JB. (1994) The flavonoids: Advances in research since 1986. London, Britain: Chapman and Hall.
18. Limtrakul P, Khantamat O, Pintha K. (2005). Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother 17:86-95. (Pubitemid 40463763)
19. Li Y, Ross-Viola JS, Shay NF, Moore DD, Ricketts ML. (2009). Human CYP3A4 and murine Cyp3A11 are regulated by equol and genistein via the pregnane X receptor in a species-specific manner. J Nutr 139:898-904.
20. Lu LJ, Anderson KE, Grady JJ, Nagamani M. (1996). Effects of soya consumption for one month on steroid hormones in premenopausal women: implications for breast cancer risk reduction. Cancer Epidemiol Biomarkers Prev 5:63-70.
21. Ma JD, Tsunoda SM, Bertino JS Jr, Trivedi M, Beale KK, Nafziger AN. (2010). Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation. Clin Pharmacokinet 49:223-237.
22. Martin J Ronis, J. Craig Rowlands, Reza Hakkak, Thomas M. Badger. (1999). Altered Expression and Glucocorticoid-Inducibility of Hepatic CYP3A and CYP2B Enzymes in Male Rats Fed Diets Containing Soy Protein Isolate. J Nutr 129:1958-1965. (Pubitemid 29506370)
23. Mirsalis JC, Hamilton CM, Schindler JE, Green CE, Dabbs JE. (1993). Effects of soya bean flakes and liquorice root extract on enzyme induction and toxicity in B6C3F1 mice. Food Chem Toxicol 31:343-350. (Pubitemid 23167381)
24. Moore LB, Parks DJ, Jones SA, Bledsoe RK, Consler TG, Stimmel JB, Goodwin B, Liddle C, Blanchard SG, Willson TM, Collins JL, Kliewer SA. (2000). Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 275:15122-15127. (Pubitemid 30337234)
25. Setchell, K. D. R. (1998) Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. American Journal of Clinical Nutrition 68 suppl: 1333S-1346S. (Pubitemid 28550909)
26. Scott LM, Durant P, Leone-Kabler S, Wood CE, Register TC, Townsend A, Cline JM. (2008). Effects of prior oral contraceptive use and soy isoflavonoids on estrogen-metabolizing cytochrome P450 enzymes. J Steroid Biochem Mol Biol 112:179-185.
27. Schwarz UI, Dresser GK, Oertel R, Kim RB. (2001)Talinolol-verapamil interaction is not solely due to P-glycoprotein inhibition (abstract PIII-86). Clin Pharmacol Ther;69:P85. (Pubitemid 33787055)
28. Schwarz UI, Gramatte T, Krappweis J, Oertel R, Kirch W. (2000). P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 38:161-167. (Pubitemid 30193611)
29. Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB, Kirch W. (2007). Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther 81:669-678. (Pubitemid 46625125)
30. Spahn-Langguth H, Langguth P. (2001). Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci 12:361-367. (Pubitemid 32166734)
31. Siegmund W, Ludwig K, Engel G, Zschiesche M, Franke G, Hoffmann A, Terhaag B, Weitschies W. (2003). Variability of intestinal expression of P-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets. J Pharm Sci 92:604-610. (Pubitemid 36258975)
32. Spahn-Langguth H, Baktir G, Radschuweit A, Okyar A, Terhaag B, Ader P, Hanafy A, Langguth P. (1998). P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 36:16-24. (Pubitemid 28031804)
33. Tindle HA, Davis RB, Phillips RS, Eisenberg DM. (2005). Trends in use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med 11:42-49. (Pubitemid 40110627)
34. Tirona RG, Lee W, Leake BF, Lan LB, Cline CB, Lamba V, Parviz F, Duncan SA, Inoue Y, Gonzalez FJ, Schuetz EG, Kim RB. (2003). The orphan nuclear receptor HNF4alpha determines PXR- and CARmediated xenobiotic induction of CYP3A4. Nat Med 9:220-224. (Pubitemid 36227725)
35. Villeneuve JP, L'Ecuyer L, De Maeght S, Bannon P. (2000). Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe. Clin Pharmacol Ther 67:242-248. (Pubitemid 30176382)
36. Wang G, Xiao CQ, Li Z, Guo D, Chen Y, Fan L, Qian RH, Peng XJ, Hu DL, Zhou HH. (2009). Effect of soy extract administration on losartan pharmacokinetics in healthy female volunteers. Ann Pharmacother 43:1045-1049.
37. Wei H, Bowen R, Cai Q, Barnes S, Wang Y. (1995). Antioxidant and antipromotional effects of the soybean isoflavone genistein. Proc Soc Exp Biol Med 208:124-130.
38. Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rosch W, Langguth P. (1996). Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm Res 13:514-522. (Pubitemid 26119052)
39. Zhou SF. (2008). Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9:310-322.